Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2002
06/26/2002EP1216222A2 Novel derivatives of dicarboxylic acid having pharmaceutical properties
06/26/2002EP1216221A2 Rxr modulators with improved pharmacologic profile
06/26/2002EP1216069A1 Method and cycler for peritoneal dialysis
06/26/2002EP1216067A1 Polyhydroxyalkanoate compositions for soft tissue repair, augmentation, and viscosupplementation
06/26/2002EP1216066A1 Compositions for the treatment of wound contracture
06/26/2002EP1216059A2 Composition for ivf
06/26/2002EP1216057A1 Stable calcitriol solution for packaging in vials
06/26/2002EP1216052A1 Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
06/26/2002EP1216050A2 Compositions for reducing sympathomimetic-induced side effects by serenoa repens extract
06/26/2002EP1216048A2 Solid lipid formulations comprising an inhibitor of lipases and a fatty acid ester of polyols
06/26/2002EP1216047A2 Novel combination of loteprednol and beta2-adrenoceptor agonists
06/26/2002EP1216046A2 Novel combination of loteprednol and antihistamines
06/26/2002EP1216045A2 Vasopressin agonist formulation and process
06/26/2002EP1216044A1 Compositions having improved stability
06/26/2002EP1216043A1 Retard form containing alpha-lipoic acid (derivatives)
06/26/2002EP1216042A1 Formulations of paclitaxel entrapped into nanoparticles of polymeric micelles
06/26/2002EP1216041A2 High lipid diet
06/26/2002EP1216040A1 Agents for reducing cholesterol-uptake and lipid-uptake
06/26/2002EP1216038A2 Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
06/26/2002EP1216037A2 Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
06/26/2002EP1216036A1 Transdermal administration of n-(2,5-disubstituted phenyl)-n'-(3-substituted phenyl)-n'-methyl guanidines
06/26/2002EP1216033A1 Vasopressin antagonist formulation and process
06/26/2002EP1216032A1 Oral controlled release formulations
06/26/2002EP1216031A2 Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
06/26/2002EP1216030A1 Anti-inflammatory pharmaceutical formulations
06/26/2002EP1216026A1 Compositions of tocol-soluble therapeutics
06/26/2002EP1216025A1 Dispersion formulations containing lipase inhibitors
06/26/2002EP1216024A1 Formulation for menopausal women
06/26/2002EP1216019A1 No-liberating topically applicable composition as biological agent, production and utilization thereof as dermatological and/or cosmetic product
06/26/2002EP1215963A2 Methods for treating neuropathic pain using hetreoarylmethanesulfonamides
06/26/2002EP1185948A4 Method for screening and producing compound libraries
06/26/2002EP1165067A4 A process for the preparation of aziridinyl epothilones from oxiranyl epothilones
06/26/2002EP1105383A4 Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
06/26/2002EP1051155B1 Nasal solutions
06/26/2002EP1049689B1 4-(2-keto-1-benzimidazolinyl)piperidine compounds as orl1-receptor agonists
06/26/2002EP1037609A4 Aqueous insecticidal pour-on formulation
06/26/2002EP1037531A4 Method of treatment of pigmented cancer cells utilizing photodynamic therapy
06/26/2002EP1007072A4 Glial cell line-derived neurotrophic factor receptors
06/26/2002EP1003517B1 Pharmaceutical composition for the treatment of so-called restless legs
06/26/2002EP1003510A4 Method for treating headache pain with topical local anesthetic compositions
06/26/2002EP0998288B1 Compositions containing capsaicin or capsaicin analogues and a local anesthetic
06/26/2002EP0973506B1 Process for preparing solid pharmaceutical dosage forms
06/26/2002EP0956011B1 Use of arachidonic acid and/or docosahexanoic acid for the manufacture of a medicament for the treatment of dyspraxia
06/26/2002EP0941065B1 Ionophore-mediated liposome loading of weakly basic drug
06/26/2002EP0931067B1 D4 receptor selectivity piperazine derivatives
06/26/2002EP0930878B1 Use of sodium 2-mercaptoethanesulfonate in surgery
06/26/2002EP0912895A4 Method for monitoring t-cell reactivity
06/26/2002EP0906120B1 Compositions comprising a combination of bone morphogenetic protein and parathyroid hormone-related peptide
06/26/2002EP0906114B1 Antipsoriatic compositions comprising an asphodelus extract, method of making, and method of using
06/26/2002EP0906096B1 Use of hydroxyprolines for the manufacture of a medicament for inhibiting leukocyte invasion of tissues
06/26/2002EP0896530B1 Dosage forms and uses
06/26/2002EP0894084B1 Cinnamic acid derivatives and their use as integrin antagonists
06/26/2002EP0888114B1 Use of (+)-alpha-(2,3-dimethoxyphenyl)-1- 2-(4-fluorophenyl)ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders
06/26/2002EP0877614B1 Method for inducing death of neoplastic cells using piperazine oxirane derivatives
06/26/2002EP0822812B1 Topical treatment and prevention of sagging subcutaneous muscle and overlying cutaneous tissue using acetylcholine precursors and catecholamines
06/26/2002EP0820441B1 INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS
06/26/2002EP0813537B1 Phosphorylated nitrone derivatives, method for preparing same, and compositions containing said derivatives
06/26/2002EP0778026B1 Remedy for endotoxinemia and multiple organ failure induced thereby
06/26/2002EP0771206B1 Hard tissue stimulating agent
06/26/2002EP0754050B1 Anti gram positive bacterial methods and materials
06/26/2002EP0692963B1 Use of terbinafine for the therapeutic treatment of pneumocystosis
06/26/2002EP0691814B1 Method and composition for treatment of osteoporosis
06/26/2002EP0644773B1 Anti-aids immunomodulator complex
06/26/2002EP0640077B1 Oxazolidinones containing a substituted diazine moiety and their use as antimicrobials
06/26/2002EP0580790B1 Method for potentiating primary drugs in treating multidrug resistant cells
06/26/2002CN1355850A Hyaluronidase from hirudinaria manillensis, isolation, purification and recombinant method of production
06/26/2002CN1355811A Integrain receptor antagaonists
06/26/2002CN1355809A Immunomodulatory steroids, in particular hemihydrate of 16 alpha-bromoepiandrosterone
06/26/2002CN1355807A Thiazoloindolinone compounds
06/26/2002CN1355805A Thienopyrimidines compound
06/26/2002CN1355802A Substituted porphyrins
06/26/2002CN1355801A Thiazolidinedione derivative and its use as antidiabetic
06/26/2002CN1355800A Thiazolidinedione derivative and use as antidiabetic
06/26/2002CN1355799A 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
06/26/2002CN1355798A 苯并咪唑化合物结晶 Benzimidazole compound crystallized
06/26/2002CN1355790A Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isindoline derivatives
06/26/2002CN1355789A Indigoid bisindole derivatives
06/26/2002CN1355788A 前列腺素e1衍生物 E1 prostaglandin derivative
06/26/2002CN1355784A Mono-and-disubstituted 2-pyrolyl gamma-aminobutric acids
06/26/2002CN1355782A Benzene derivatives, preparation method and pharmaceutical compositions containing same
06/26/2002CN1355713A Releasable bond and composition containing said bond
06/26/2002CN1355710A Combination vaccine against streptocouus pneumoniae and repiratory syncytial virus (RSV)
06/26/2002CN1355708A HCV combination therapy containing ribavirin in association with antioxidants
06/26/2002CN1355706A 因子 Factor
06/26/2002CN1355703A Therapeutical agent
06/26/2002CN1355702A Use of arylalkanoylpyridazines
06/26/2002CN1355701A Urea substituted imidazoquinolines
06/26/2002CN1355700A 皮肤麻醉剂 Skin anesthetic
06/26/2002CN1355699A Antifungal compositions
06/26/2002CN1355698A Compound for medicine for treating function of bronchial contraction
06/26/2002CN1355697A IL-8 receptor antagonists
06/26/2002CN1355696A Method to aid smoking cessation
06/26/2002CN1355695A Compounds useful in reducing level of insulin like growth factor-I (IGF-I) in blood
06/26/2002CN1355694A Measalazine controlled redease oral pharmaceutical compositions
06/26/2002CN1355693A Controlled release and taste masking oral pharmaceutical compositions
06/26/2002CN1355691A Antibody and polyalkylene glycol-bonded liposome
06/26/2002CN1355690A Method for improving half-life of soluble viral-specific ligands on mucosal membranes
06/26/2002CN1355689A Methods for regulating condition of mammalian keratinous tissue
06/26/2002CN1355687A Anhydrous antiperspirant cream compositions having improved perfume longevity
06/26/2002CN1355686A Micropigment mixture